NZ299257A - Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase - Google Patents

Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase

Info

Publication number
NZ299257A
NZ299257A NZ29925796A NZ29925796A NZ299257A NZ 299257 A NZ299257 A NZ 299257A NZ 29925796 A NZ29925796 A NZ 29925796A NZ 29925796 A NZ29925796 A NZ 29925796A NZ 299257 A NZ299257 A NZ 299257A
Authority
NZ
New Zealand
Prior art keywords
accumulation
patients
pulmonary disease
purulent material
treating purulent
Prior art date
Application number
NZ29925796A
Inventor
John Henry Frenz
Steven Jacob Shire
Mary Burke Sliwkowski
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NZ299257A publication Critical patent/NZ299257A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The use of deaminated human Dnase in the manufacture of a medicament for the treatment of accumulated purulent material and pulmonary diseases.
NZ29925796A 1992-06-08 1996-08-29 Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase NZ299257A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8953392A 1992-06-08 1992-06-08

Publications (1)

Publication Number Publication Date
NZ299257A true NZ299257A (en) 2000-08-25

Family

ID=22218180

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ29925796A NZ299257A (en) 1992-06-08 1996-08-29 Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase

Country Status (1)

Country Link
NZ (1) NZ299257A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8871200B2 (en) 2006-11-28 2014-10-28 Cls Therapeutics Limited Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
US8916151B2 (en) 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
US11701410B2 (en) 2015-05-22 2023-07-18 Cls Therapeutics Limited Extracellular DNA as a therapeutic target in neurodegeneration
US11905522B2 (en) 2018-01-16 2024-02-20 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463223B2 (en) 2003-07-14 2016-10-11 Cls Therapeutics Limited Method for monitoring development of somatic mosaicism
US9248166B2 (en) 2003-07-14 2016-02-02 Cls Therapeutics Limited Method for treating oncological diseases
US8535663B2 (en) 2003-07-14 2013-09-17 Cls Therapeutics Limited Method for treating delayed-type hypersensitivity
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8796004B2 (en) 2003-07-14 2014-08-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US9845461B2 (en) 2003-07-14 2017-12-19 Cls Therapeutics Limited Method for treating oncological diseases
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US9072733B2 (en) 2003-07-14 2015-07-07 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US9770492B2 (en) 2003-07-14 2017-09-26 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8916151B2 (en) 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
US8871200B2 (en) 2006-11-28 2014-10-28 Cls Therapeutics Limited Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
US11701410B2 (en) 2015-05-22 2023-07-18 Cls Therapeutics Limited Extracellular DNA as a therapeutic target in neurodegeneration
US11905522B2 (en) 2018-01-16 2024-02-20 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity

Similar Documents

Publication Publication Date Title
HU9301978D0 (en) Application of complementary inhibitors in medical preparatives used for treatment of inflammatory diseases of intestines and skin
HU9602583D0 (en) Gel for treatment of skin diseases and for disinfection of the skin
CA2116559A1 (en) Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
NZ501069A (en) Monoesters of probucol for the treatment of cardiovascular and inflammatory disease
DE69721766D1 (en) NEW MEDICAL FORMULATION
PT668763E (en) USE OF FENSERIN FOR THE PREPARATION OF MEDICINES TO TREAT DISEASES OF KNOWLEDGE
AU1197992A (en) The use of loperamide and related compounds for treatment of respiratory disease symptoms
NO933000D0 (en) USE OF C1 INACTIVATOR FOR THE PREPARATION OF A MEDICINE FOR PROPHYLAXY AND TREATMENT OF CERTAIN DISEASES
NZ299257A (en) Treating purulent material (eg pulmonary disease) accumulation in patients using deamidated DNase
IL112288A (en) Use of riluzole in the manufacture of a medicament for the treatment of mitochondrial diseases
EP0744176A3 (en) Methods for inhibiting bone loss
AU3733295A (en) Treatment of obstructive airway disease by administering thymosin beta 4, or coadministration of thymosin beta 4 and dnase i
EP0795332A3 (en) Medical use of gamma-interferon in interstitial lung diseases
AU1898792A (en) Treatment or therapeutic booth for energetic, cosmetic and medical purposes
NZ307601A (en) Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions
AU2143892A (en) Use of formoterol for treatment of tissue injury
ZA933567B (en) Use of (E)-2-(p-fluorophenethyl)-3-fluoroallylamine in the treatment of Alzheimer's disease
NO307126B1 (en) Use of biologically active ureido derivatives for the manufacture of a medicament for use in the treatment of lentivirus-induced disease
NZ268039A (en) Use of efaroxan in treating parkinson's disease
WO2001019359A3 (en) Medicaments containing pantothenic acid for the treatment of inflammatory joint disease
MY112888A (en) Use of bradykinin antagonists for the preparation of medicaments for the treatment of virus diseases.
EP0673646A3 (en) Use of Deoxypergualin in the manufacture of a medicament for the treatment of inflammatory-hyperresponsiveness diseases.
AU8195091A (en) Ropinirole and domperidone for use in the manufacture of a medicament for the treatment of parkinson's disease
LV5179A3 (en) Preparation of "ethoxidine" for prophylaxis and treatment of almost all diseases of the lungs and bowels
WO1998024421A3 (en) Use of dextrin sulphate for the treatment of highly vascular tumours

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired